Caitlin C Murphy1, Linda C Harlan2, Joan L Warren2, Ann M Geiger2. 1. Caitlin C. Murphy, University of North Carolina at Chapel Hill, Chapel Hill, NC; and Linda C. Harlan, Joan L. Warren, Ann M. Geiger, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD. caitlin_murphy@med.unc.edu. 2. Caitlin C. Murphy, University of North Carolina at Chapel Hill, Chapel Hill, NC; and Linda C. Harlan, Joan L. Warren, Ann M. Geiger, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD.
Abstract
PURPOSE: Although the incidence and mortality of colon cancer in the United States has declined over the past two decades, blacks have worse outcomes than whites. Variations in treatment may contribute to mortality differentials. METHODS: Patients diagnosed with stage III colon cancer were randomly sampled from the SEER program from the years 1990, 1991, 1995, 2000, 2005, and 2010. Patients were categorized as non-Hispanic white (n = 835) or black (n = 384). Treatment data were obtained from a review of the medical records, and these data were verified through contact with the original treating physicians. Log-binomial regression models were used to estimate the association between race and receipt of adjuvant chemotherapy. Effect modification by insurance was assessed with use of single referent models. RESULTS: Receipt of adjuvant chemotherapy among both white and black patients increased from the period encompassing the years 1990 and 1991 (white, 58%; black, 45%) to the year 2005 (white, 72%; black, 71%) and then decreased in the year 2010 (white, 66%; black, 57%). There were marked racial disparities in the time period of 1990 to 1991 and again in 2010, with black patients less likely to receive adjuvant chemotherapy as compared with white patients (risk ratio [RR], .82; 95% CI, .72 to .93). For black patients, receipt of adjuvant chemotherapy did not differ across insurance categories (RR for private insurance, .80; 95% CI, .69 to .93; RR for Medicare, .84; 95% CI, .69 to 1.02; and RR for Medicaid, .84; 95% CI, .69 to 1.02), although a larger proportion had Medicaid in all years of the study as compared with white patients. CONCLUSION: The chemotherapy differential narrowed after the time period of 1990 to 1991, but our findings suggest that the disparity reemerged in 2010. Recent decreases in chemotherapy use may be due, in part, to the economic downturn and an increase in Medicaid coverage.
PURPOSE: Although the incidence and mortality of colon cancer in the United States has declined over the past two decades, blacks have worse outcomes than whites. Variations in treatment may contribute to mortality differentials. METHODS: Patients diagnosed with stage III colon cancer were randomly sampled from the SEER program from the years 1990, 1991, 1995, 2000, 2005, and 2010. Patients were categorized as non-Hispanic white (n = 835) or black (n = 384). Treatment data were obtained from a review of the medical records, and these data were verified through contact with the original treating physicians. Log-binomial regression models were used to estimate the association between race and receipt of adjuvant chemotherapy. Effect modification by insurance was assessed with use of single referent models. RESULTS: Receipt of adjuvant chemotherapy among both white and black patients increased from the period encompassing the years 1990 and 1991 (white, 58%; black, 45%) to the year 2005 (white, 72%; black, 71%) and then decreased in the year 2010 (white, 66%; black, 57%). There were marked racial disparities in the time period of 1990 to 1991 and again in 2010, with black patients less likely to receive adjuvant chemotherapy as compared with white patients (risk ratio [RR], .82; 95% CI, .72 to .93). For black patients, receipt of adjuvant chemotherapy did not differ across insurance categories (RR for private insurance, .80; 95% CI, .69 to .93; RR for Medicare, .84; 95% CI, .69 to 1.02; and RR for Medicaid, .84; 95% CI, .69 to 1.02), although a larger proportion had Medicaid in all years of the study as compared with white patients. CONCLUSION: The chemotherapy differential narrowed after the time period of 1990 to 1991, but our findings suggest that the disparity reemerged in 2010. Recent decreases in chemotherapy use may be due, in part, to the economic downturn and an increase in Medicaid coverage.
Authors: Gery P Guy; Donatus U Ekwueme; K Robin Yabroff; Emily C Dowling; Chunyu Li; Juan L Rodriguez; Janet S de Moor; Katherine S Virgo Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Emily C Dowling; Neetu Chawla; Laura P Forsythe; Janet de Moor; Timothy McNeel; Heather M Rozjabek; Donatus U Ekwueme; K Robin Yabroff Journal: Cancer Date: 2013-06-21 Impact factor: 6.860
Authors: Erin E Kent; Laura P Forsythe; K Robin Yabroff; Kathryn E Weaver; Janet S de Moor; Juan L Rodriguez; Julia H Rowland Journal: Cancer Date: 2013-07-31 Impact factor: 6.860
Authors: Chyke A Doubeni; Adeyinka O Laiyemo; Jacqueline M Major; Mario Schootman; Min Lian; Yikyung Park; Barry I Graubard; Albert R Hollenbeck; Rashmi Sinha Journal: Cancer Date: 2012-01-03 Impact factor: 6.860
Authors: Iris Lansdorp-Vogelaar; Karen M Kuntz; Amy B Knudsen; Marjolein van Ballegooijen; Ann G Zauber; Ahmedin Jemal Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-04-18 Impact factor: 4.254
Authors: Chyke A Doubeni; Jacqueline M Major; Adeyinka O Laiyemo; Mario Schootman; Ann G Zauber; Albert R Hollenbeck; Rashmi Sinha; Jeroan Allison Journal: J Natl Cancer Inst Date: 2012-09-05 Impact factor: 13.506
Authors: Donatus U Ekwueme; K Robin Yabroff; Gery P Guy; Matthew P Banegas; Janet S de Moor; Chunyu Li; Xuesong Han; Zhiyuan Zheng; Anita Soni; Amy Davidoff; Ruth Rechis; Katherine S Virgo Journal: MMWR Morb Mortal Wkly Rep Date: 2014-06-13 Impact factor: 17.586
Authors: Susan Eggly; Lauren M Hamel; Tanina S Foster; Terrance L Albrecht; Robert Chapman; Felicity W K Harper; Hayley Thompson; Jennifer J Griggs; Richard Gonzalez; Lisa Berry-Bobovski; Rifky Tkatch; Michael Simon; Anthony Shields; Shirish Gadgeel; Randa Loutfi; Haythem Ali; Ira Wollner; Louis A Penner Journal: Patient Educ Couns Date: 2016-12-27
Authors: Tomi F Akinyemiju; Gurudatta Naik; Kemi Ogunsina; Daniel T Dibaba; Neomi Vin-Raviv Journal: Cancer Causes Control Date: 2018-02-10 Impact factor: 2.506
Authors: Louis A Penner; John F Dovidio; Richard Gonzalez; Terrance L Albrecht; Robert Chapman; Tanina Foster; Felicity W K Harper; Nao Hagiwara; Lauren M Hamel; Anthony F Shields; Shirish Gadgeel; Michael S Simon; Jennifer J Griggs; Susan Eggly Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Louis A Penner; John F Dovidio; Nao Hagiwara; Tanina Foster; Terrance L Albrecht; Robert A Chapman; Susan Eggly Journal: J Health Care Poor Underserved Date: 2016
Authors: Talha Shaikh; Elizabeth A Handorf; Joshua E Meyer; Michael J Hall; Nestor F Esnaola Journal: JAMA Oncol Date: 2018-02-08 Impact factor: 31.777